Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Efficacy and Safety of GV-971 in Alzheimer's Disease
NCT05181475Phase 4Active, not recruiting
- Sponsor
- Green Valley
- Start
- Dec 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sodium oligomannate in Alzheimer's disease (AD), sponsored by Green Valley. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale 11-Item at 48 weeks. Started Dec 2021; status: active, not recruiting.
02
Drugs
sodium oligomannate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05181475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181475.